At RayzeBio, a wholly-owned subsidiary of Bristol Myers Squibb, the mission is to develop transformative radiopharmaceutical therapies for cancer patients. The company blends the agile spirit of a biotech with the resources of a leading oncology innovator. RayzeBio, headquartered in San Diego, CA, was launched in late 2020 and acquired by BMS in 2024. It operates as a standalone entity, focusing on improving cancer survival through targeted radioisotopes. RayzeBio is developing innovative drugs against solid tumor targets, with its lead asset, RYZ101, in Phase 3 testing for GEP-NETs and earlier stage testing for SCLC. The company is led by an experienced entrepreneurial team aiming to be a global leader in radiopharmaceuticals. This laboratory-based role offers an opportunity to advance novel radiopharmaceutical therapies from the lab into clinical testing. The candidate will be responsible for developing, optimizing, and transferring biochemical and cell-based assays, including equilibrium binding assays, to support target validation, compound screening, and mechanism of action studies for various pipeline projects. A strong foundation in mammalian cell culture is essential. The ideal candidate is a critical thinker and technical problem solver who enjoys interdisciplinary drug discovery teams and is willing to work with radioactive isotopes.
Stand Out From the Crowd
Upload your resume and get instant feedback on how well it matches this job.
Job Type
Full-time
Career Level
Mid Level
Number of Employees
5,001-10,000 employees